A team of researchers at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute has discovered a set of 3 measurable risk factors that can help predict the magnitude of survival benefit offered by radiation therapy following breast-conserving surgery for ductal carcinoma in situ.
Bupivacaine liposome injectable suspension (Exparel) was found to be similarly effective in reducing pain compared with conventional bupivacaine HCL, but reduced ileus, nausea, and the need for patient-controlled analgesia and rescue IV opioid use.
Supplements are not regulated in the same way that prescription medications are regulated in the United States; consequently, the supplement market, which includes vitamins, probiotics, fish oils, etc, has greatly expanded over the past decade.
At the 2016 NCCN Annual Conference, William J. Gradishar, MD, a professor of Breast Oncology at the Feinberg School of Medicine at Northwestern University, discussed updates to the NCCN Breast Cancer Guideline and the latest research developments in the field.
The spotlight was on improving palliative cancer care at the opening session of the 2016 NCCN Annual Meeting, with a panel of experts stressing the importance of delivering these services earlier in the cancer care trajectory and involving teams in the effort.
A nomogram calculates the risk of ipsilateral breast tumor recurrence after breast-conserving surgery.
The FDA has approved a new agent for the treatment of severe hepatic veno-occlusive disease, a rare but often fatal complication in patients who receive chemotherapy and hematopoietic stem cell transplantation.
Research has identified a correlation between a diet with a high glycemic index and an increased risk of developing lung cancer in non-Hispanic whites.
Much work needs to be done to increase Lynch syndrome screening rates and better understand the factors that are associated with low testing rates.
The American Cancer Society has issued a new clinical practice guideline for the follow-up screening and care coordination for this population of survivors, who may experience significant physical, psychosocial, and practical effects from their cancer and its treatment.
A study published by researchers at the Dana Farber-Cancer Institute recently discovered that financial status plays a large role in the level of symptom burden and quality of life for patients newly diagnosed with lung or colorectal cancer.
Findings from a randomized trial reported at the 2016 Annual Meeting of the Society of Gynecologic Oncology showed that APF530, an extended-release formulation of the antiemetic granisetron, achieved a complete response more often than did ondansetron in patients receiving highly emetogenic cisplatin-based chemotherapy.
Pregnant and diagnosed with cervical cancer at age 27, I chose treatment and my daughter and I survived what experts said would kill us.
Again this year, the American Society of Clinical Oncology has released its report on the state of cancer care in the United States.
A majority of patients with cancer who undergo chemotherapy experience neuropathy as result of the treatment, and a new study conducted by researchers at The University of Texas MD Anderson Cancer Center suggests that neurofeedback can reduce the pain associated with the condition and improve quality of life.
A new study by physicians has found that Twitter may be an effective and heretofore untapped resource to stimulate interest in cancer clinical trials and boost enrollment.
Is there a treatment-related survival benefit for older patients with metastatic colorectal cancer?
Crizotinib (Xalkori) has been approved by the FDA as a treatment for patients with ROS1-positive metastatic non–small cell lung cancer.
Drawing a standing ovation from a packed room of oncology professionals attending the 33rd Annual Miami Breast Cancer Conference®, breast cancer survivor and Good Morning America news anchor Amy Robach criticized new US Preventive Services Task Force guidelines that extend the recommended age to begin mammogram screening to age 50 for women at average risk.
Bright Pink's Women's Health Provider Education program is designed to address gaps in knowledge of young women's genetic cancer risk.
The results of this study underscore the importance of advance care planning in improving the quality of care that patients receive at end-of-life.
Encouraging findings for PD-1 inhibitor–based immunotherapies for the treatment of patients with metastatic head and neck cancer are emerging from clinical studies.
The American Society of Clinical Oncology convened a panel of experts to provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer.
An impressive improvement in progression-free survival (PFS) in the RESONATE-2 trial led to the FDA’s approval of ibrutinib (Imbruvica) March 4 for the frontline treatment of chronic lymphocytic leukemia, based on data from the RESONATE-2 trial.
